Abpro Bio Co., Ltd. (KOSDAQ:195990)
South Korea
· Delayed Price · Currency is KRW 310.00
-1.00 (-0.32%)
Last updated: Apr 1, 2025
Abpro Bio Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 31,663 | 25,375 | 22,112 | 32,914 | 35,797 | Upgrade
|
| Other Revenue | - | - | -0 | - | - | Upgrade
|
| Revenue | 31,663 | 25,375 | 22,112 | 32,914 | 35,797 | Upgrade
|
| Revenue Growth (YoY) | 24.78% | 14.76% | -32.82% | -8.05% | 12.11% | Upgrade
|
| Cost of Revenue | 31,047 | 24,107 | 20,493 | 28,986 | 30,195 | Upgrade
|
| Gross Profit | 616.3 | 1,269 | 1,619 | 3,928 | 5,602 | Upgrade
|
| Selling, General & Admin | 9,246 | 8,269 | 8,544 | 7,848 | 4,974 | Upgrade
|
| Research & Development | 448.27 | 573.04 | 879.91 | 562.3 | 519.15 | Upgrade
|
| Other Operating Expenses | 444.94 | 323.52 | 251.64 | 433.14 | 335.11 | Upgrade
|
| Operating Expenses | 7,159 | 11,444 | 12,813 | 9,261 | 7,493 | Upgrade
|
| Operating Income | -6,543 | -10,175 | -11,193 | -5,333 | -1,891 | Upgrade
|
| Interest Expense | -2,090 | -2,341 | -4,591 | -6,859 | -4,946 | Upgrade
|
| Interest & Investment Income | 654.29 | 301.52 | 167.66 | 576.37 | 468.58 | Upgrade
|
| Earnings From Equity Investments | -27,881 | -9,377 | 4,219 | -5,876 | -12,984 | Upgrade
|
| Currency Exchange Gain (Loss) | 7,204 | 520.54 | 1,760 | 2,388 | -1,179 | Upgrade
|
| Other Non Operating Income (Expenses) | 2,986 | -1,015 | -867.14 | 8,613 | -19,725 | Upgrade
|
| EBT Excluding Unusual Items | -25,669 | -22,086 | -10,505 | -6,491 | -40,257 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.58 | 16.29 | 2,520 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 11,804 | -2,559 | 328.51 | 650.04 | -190.14 | Upgrade
|
| Asset Writedown | -2,191 | -1,029 | -487.48 | -3,834 | -759.42 | Upgrade
|
| Pretax Income | -16,056 | -25,658 | -8,145 | -9,675 | -41,207 | Upgrade
|
| Income Tax Expense | -426.12 | 84.12 | - | 64.59 | 3,548 | Upgrade
|
| Earnings From Continuing Operations | -15,629 | -25,742 | -8,145 | -9,740 | -44,755 | Upgrade
|
| Earnings From Discontinued Operations | - | - | - | -775.31 | -16,862 | Upgrade
|
| Net Income to Company | -15,629 | -25,742 | -8,145 | -10,515 | -61,617 | Upgrade
|
| Minority Interest in Earnings | - | - | - | 484.68 | 2,645 | Upgrade
|
| Net Income | -15,629 | -25,742 | -8,145 | -10,030 | -58,972 | Upgrade
|
| Net Income to Common | -15,629 | -25,742 | -8,145 | -10,030 | -58,972 | Upgrade
|
| Shares Outstanding (Basic) | 285 | 278 | 268 | 252 | 213 | Upgrade
|
| Shares Outstanding (Diluted) | 285 | 278 | 268 | 270 | 214 | Upgrade
|
| Shares Change (YoY) | 2.31% | 3.72% | -0.50% | 25.82% | 64.14% | Upgrade
|
| EPS (Basic) | -54.90 | -92.51 | -30.36 | -39.85 | -276.73 | Upgrade
|
| EPS (Diluted) | -54.90 | -92.51 | -30.36 | -43.31 | -304.43 | Upgrade
|
| Free Cash Flow | -22,861 | -6,011 | -12,593 | -2,762 | 2,490 | Upgrade
|
| Free Cash Flow Per Share | -80.30 | -21.60 | -46.94 | -10.24 | 11.62 | Upgrade
|
| Gross Margin | 1.95% | 5.00% | 7.32% | 11.93% | 15.65% | Upgrade
|
| Operating Margin | -20.66% | -40.10% | -50.62% | -16.20% | -5.28% | Upgrade
|
| Profit Margin | -49.36% | -101.45% | -36.83% | -30.47% | -164.74% | Upgrade
|
| Free Cash Flow Margin | -72.20% | -23.69% | -56.95% | -8.39% | 6.96% | Upgrade
|
| EBITDA | -5,059 | -8,305 | -9,791 | -2,708 | 5,357 | Upgrade
|
| EBITDA Margin | -15.98% | -32.73% | -44.28% | -8.23% | 14.96% | Upgrade
|
| D&A For EBITDA | 1,484 | 1,870 | 1,402 | 2,625 | 7,248 | Upgrade
|
| EBIT | -6,543 | -10,175 | -11,193 | -5,333 | -1,891 | Upgrade
|
| EBIT Margin | -20.66% | -40.10% | -50.62% | -16.20% | -5.28% | Upgrade
|
| Advertising Expenses | 2.3 | 1.92 | 297.47 | 163.47 | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.